Compounding Related Topics 
Fierce Pharma
OCTOBER 8, 2024
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.”
STAT
OCTOBER 11, 2024
The move was a clear warning to compounders that they can no longer make copycat versions of the drugs — a process that is only permitted when the medications are on an official agency shortage list. Read the rest…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 14, 2024
Four days after a compounding industry group filed a lawsuit against the FDA | Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products from its shortage list, the U.S. regulator is taking a second look at its decision.
pharmaphorum
OCTOBER 14, 2024
Faced with lawsuit, FDA rethinks block on compounding pharmacies making Eli Lilly's diabetes and obesity drug tirzepatide
STAT
OCTOBER 8, 2024
A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list.
Drug Topics
NOVEMBER 15, 2023
Compounding parenteral nutrition solutions is a complex process with a high risk for error, which can lead to serious adverse outcomes.
Drug Topics
DECEMBER 13, 2023
Kevin Hope, RPh, senior director of pharmacy education at Pharmcon, joined Drug Topics to discuss pharmacy compounding from the new USP changes and the importance of education around compounding best practices.
Expert insights. Personalized for you.
129 
Let's personalize your content